Silenseed
Jerusalem
About Silenseed
Silenseed is a clinical stage biopharmaceutical company that develops proprietary RNA interference (RNAi)-based cancer drugs and delivery systems designed to effectively penetrate and treat malignant solid tumors. The company’ novel drugs, used together with the new delivery system, the LODER™ (LOcal Drug EluteR), have the potential to be one of the most highly effective treatments for solid tumor cancers. Diseases that currently are included in the company’s pipeline are pancreatic cancer, prostate cancer and certain brain cancers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $10.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2020)
- Website: silenseed.com
- Phone: 972 2 674 3430
Industries & Categories
Biopharma, Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/silenseed-28713 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.